Oncology therapies have been advancing at a rapid pace over the past decade. In the past, systemic therapy for malignancies mainly relied on cytotoxic chemotherapies. More recently, a wide variety of novel therapeutics have been developed for treating metastatic malignancies, including chimeric antigen receptor T-cell (CAR-T), immune checkpoint inhibitors (ICIs), bispecific antibodies, and antibody drug conjugates (ADCs). Most of these emerging oncological therapies have been shown to be safe and efficacious in randomized controlled trials. Nethertheless, it is still critical to review post-marketing real world data in order to gain a more comprehensive understanding of their cardiovascular safety.
Led by an international team of subject experts, this research topic will identify real world prevalence and severity of cardiovascular complications associated with emerging oncological therapies. Sub-themes include, but are not limited to:
- Real world prevalence and severity of cardiovascular complications associated with emerging oncological therapies
- Potential treatment strategies to mitigate cardiovascular complications associated with emerging oncological therapies
The topic editors encourage submission of all manuscript types with a particular focus on original research, case reports, and review articles.
Oncology therapies have been advancing at a rapid pace over the past decade. In the past, systemic therapy for malignancies mainly relied on cytotoxic chemotherapies. More recently, a wide variety of novel therapeutics have been developed for treating metastatic malignancies, including chimeric antigen receptor T-cell (CAR-T), immune checkpoint inhibitors (ICIs), bispecific antibodies, and antibody drug conjugates (ADCs). Most of these emerging oncological therapies have been shown to be safe and efficacious in randomized controlled trials. Nethertheless, it is still critical to review post-marketing real world data in order to gain a more comprehensive understanding of their cardiovascular safety.
Led by an international team of subject experts, this research topic will identify real world prevalence and severity of cardiovascular complications associated with emerging oncological therapies. Sub-themes include, but are not limited to:
- Real world prevalence and severity of cardiovascular complications associated with emerging oncological therapies
- Potential treatment strategies to mitigate cardiovascular complications associated with emerging oncological therapies
The topic editors encourage submission of all manuscript types with a particular focus on original research, case reports, and review articles.
